Pharmacokinetics of oxypolygelatine in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 49-51

  Thurmann P A ^a   Lissner, R ^b   Struff, W G ^b   Harder, S ^c  

^a HELIOS KLINIKUM WUPPERTAL   (Germany)

^b BIOTEST AG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Healthy volunteers; Oxypolygelatine; Pharmacokinetics; Tolerability

Indexed keywords

CLEMASTINE; OXYPOLYGELATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; EXTRAVASCULAR SPACE; EYELID EDEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

CONTRAST MEDIA; FEMALE; GELATIN; HUMANS; MALE; TISSUE DISTRIBUTION;

EID: 0033003463     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050591     Document Type: Article

References (10)

1. Roberts JS, Bratton SL (1998) Colloid volume expanders: problems, pitfalls and possibilities. Drugs 55: 621-630
2. EG-Document III/3385/92; Final (1997) Minimizing the risk of transmitting agents causing spongiform encephalopathy via veterinary products. In: Feiden K (ed) Arzncimittelprüfrichtlinien. Wissenschaftliche Verlagsgesellschaft, Stuttgart, chapter 2.79, pp 1-6
3. Laxenaire MC, Charpentier C, Feldman L (1994) Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reanim 13: 301-310
4. Stryuer L (1988) Biochemistry. Chapter 11: Connective tissue proteins, 3rd edn. W. H. Freeman, New York
5. Stegemann H, Stalder K (1967) Determination of hydroxyproline. Clin Chim Acta 18: 267-273
6. Heinzel G, Woloszcak R, Thomann P (1993) Pharmacokinetic and pharmacodynamic data analysis system for the PC. Version 2.0. Gustav Fischer, Stuttgart
7. Köhler H, Zschiedrich H, Linfante A, Appel F, Pitz H, Clasen R (1982) Die Elimination von Hydroxyäthylstärke 200/0,5, Dextran 40 und Oxypolygelatine. Klin Wochenschr 60: 293-301
8. Köhler H, Kirch W, Fuchs P, Stalder K, Distler A (1978) Elimination of hexamethylene diisocyanate cross-linked polypeptides in patients with normal or impaired renal function. Eur J Clin Pharmacol 14: 405-412
9. Bambauer R, Stolz D, El-Saadie R, Stelzer K, Jutzler GA (1984) Verhalten von Oxypolygelatine (Gelifundol®) bei Patienten mit dialysepflichtiger Niereninsuffizienz. Infusther Klin Ernähr II: 3-7
10. Zekorn D (1969) Intravascular retention, dispersal, excretion and break-down of gelatin plasma substitutes. Bibl Haematol 33: 131-140